ASCO GU: Current thinking in mCRPC

Overtreatment of low risk prostate cancer: incidence in USA, cost, complications and implications

Effect of therapeutic anticoagulation on overall survival in men receiving docetaxel for mCRPC

Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer

Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up

Pelvic radiotherapy and androgen blockade for high risk prostate cancer

TIVO 1 study shows tivozanib an option for renal cell carcinoma

Chemo-radiotherapy for bladder cancer

Prediction of relapse in stage I nonseminomatous germ cell tumors by CXCL12